[go: up one dir, main page]

NO20054710L - Immunmodulerende heterosykliske forbindelser - Google Patents

Immunmodulerende heterosykliske forbindelser

Info

Publication number
NO20054710L
NO20054710L NO20054710A NO20054710A NO20054710L NO 20054710 L NO20054710 L NO 20054710L NO 20054710 A NO20054710 A NO 20054710A NO 20054710 A NO20054710 A NO 20054710A NO 20054710 L NO20054710 L NO 20054710L
Authority
NO
Norway
Prior art keywords
heterocyclic compounds
immunomodulating
immunomodulating heterocyclic
solvate
hydrate
Prior art date
Application number
NO20054710A
Other languages
English (en)
Other versions
NO332136B1 (no
NO20054710D0 (no
Inventor
Ian Richard Mathews
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of NO20054710D0 publication Critical patent/NO20054710D0/no
Publication of NO20054710L publication Critical patent/NO20054710L/no
Publication of NO332136B1 publication Critical patent/NO332136B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forbindelser med formel (I) er inhibitorer for CD80 og anvendbare i immunomodulasjonsterapi: hvor Ri og R3 uavhengig av hverandre er H, F, Cl, Br, -NO2, -CN, C1-C6 alkyl eventuelt substituert med F eller Cl, eller C1-C6 alkoksy eventuelt substituert med F; R4 er en karboksylsyregruppe (-COOH) eller en ester derav, eller -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 eller -NHC(=S)NR7R6 hvor Re er H, eller et radikal med formel -(Alk)m-Q hvor m is 0 or 1, Alk er et eventuelt substituert, toverdig, rettkjedet eller forgrenet C1-C12 alkylen-, C2-C12 alkenylen-, C2-C12 alkynylenradikal eller et toverdig C3-C12 karbosyklisk radikal, hvor alle radikalene kan inneholde en eller flere -O-, -S- eller -N(R8)-linkere hvor R8 er H eller d-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl eller C3-C6 sykloalkyl, og Q er H, -NRgRiohvor R9 og Rio uavhengig av hverandre er H, C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, C3-C6 sykloalkyl, en estergruppe, en eventuelt substituert karbosyklisk eller heterosyklisk gruppe, eller R9 og Rio danner en ring sammen med nitrogenet som de er
NO20054710A 2003-03-14 2005-10-13 Immunomodulerende heterosyklisk forbindelse, anvendelse derav for fremstilling av et medikament, og farmasoytisk eller veterinaermedisinsk preparat omfattende forbindelsen NO332136B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds
PCT/GB2004/001008 WO2004081011A1 (en) 2003-03-14 2004-03-10 Immunomodulating heterocyclic compounds

Publications (3)

Publication Number Publication Date
NO20054710D0 NO20054710D0 (no) 2005-10-13
NO20054710L true NO20054710L (no) 2005-12-13
NO332136B1 NO332136B1 (no) 2012-07-02

Family

ID=32992598

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054710A NO332136B1 (no) 2003-03-14 2005-10-13 Immunomodulerende heterosyklisk forbindelse, anvendelse derav for fremstilling av et medikament, og farmasoytisk eller veterinaermedisinsk preparat omfattende forbindelsen

Country Status (20)

Country Link
US (3) US7276505B2 (no)
EP (2) EP1603917B1 (no)
JP (1) JP4892338B2 (no)
KR (1) KR101133959B1 (no)
AT (1) ATE489388T1 (no)
BR (1) BRPI0408365B8 (no)
CA (1) CA2519063C (no)
DE (1) DE602004030225D1 (no)
DK (1) DK1603917T3 (no)
EA (2) EA009680B1 (no)
EC (1) ECSP056104A (no)
HK (1) HK1090921A1 (no)
IL (1) IL170389A (no)
MX (1) MXPA05009667A (no)
NO (1) NO332136B1 (no)
NZ (1) NZ541973A (no)
PL (2) PL383655A1 (no)
PT (1) PT1603917E (no)
SI (1) SI1603917T1 (no)
WO (1) WO2004081011A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009680B1 (ru) * 2003-03-14 2008-02-28 Эвидекс Лимитед Иммуномодулирующие гетероциклические соединения
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
MX2007001238A (es) * 2004-08-09 2007-04-17 Avidex Ltd Oxopirazolocinolinas inmunomoduladoras como inhibidores de moleculas cd80.
CA2618888A1 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
EP2047848A4 (en) * 2006-07-05 2010-06-09 Univ Tokyo METHOD FOR THE TREATMENT OF GENETIC DISEASES BASED ON A NONSENSE MUTATION
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
WO2009012252A1 (en) 2007-07-16 2009-01-22 Wyeth Aminoalkylazole derivatives as histamine-3 antagonists
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
CN101815512B (zh) 2007-10-04 2013-04-24 弗·哈夫曼-拉罗切有限公司 环丙基芳基酰胺衍生物和其用途
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
AU2015315177A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
WO2018110669A1 (en) * 2016-12-15 2018-06-21 Ono Pharmaceutical Co., Ltd. Activator of trek (twik related k+ channels) channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) * 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
EP0269030B1 (en) 1986-11-20 1994-05-04 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
WO2003004485A1 (en) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
DE60311861T2 (de) 2002-11-22 2007-11-22 Active Biotech Ab Pyrazolochinoline mit immunmodulierender wirkung
AU2003287129A1 (en) 2002-12-16 2004-07-09 Active Biotech Ab Tetracyclic immunomodulatory compounds
EA009680B1 (ru) * 2003-03-14 2008-02-28 Эвидекс Лимитед Иммуномодулирующие гетероциклические соединения
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
MX2007001238A (es) * 2004-08-09 2007-04-17 Avidex Ltd Oxopirazolocinolinas inmunomoduladoras como inhibidores de moleculas cd80.
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
JP2006520372A (ja) 2006-09-07
NZ541973A (en) 2009-06-26
EP1603917A1 (en) 2005-12-14
CA2519063C (en) 2011-05-10
CA2519063A1 (en) 2004-09-23
PT1603917E (pt) 2011-02-04
EP2284172A1 (en) 2011-02-16
IL170389A (en) 2013-08-29
MXPA05009667A (es) 2006-01-27
PL383655A1 (pl) 2008-04-14
EP1603917B1 (en) 2010-11-24
US20090312334A1 (en) 2009-12-17
EA009680B1 (ru) 2008-02-28
BRPI0408365B1 (pt) 2018-11-21
BRPI0408365B8 (pt) 2021-05-25
NO332136B1 (no) 2012-07-02
US7276505B2 (en) 2007-10-02
AU2004220310A1 (en) 2004-09-23
DK1603917T3 (da) 2011-02-28
KR101133959B1 (ko) 2012-04-09
JP4892338B2 (ja) 2012-03-07
US8309552B2 (en) 2012-11-13
PL1603917T3 (pl) 2011-12-30
SI1603917T1 (sl) 2011-04-29
US7598247B2 (en) 2009-10-06
EA200501370A1 (ru) 2006-08-25
EA200702435A1 (ru) 2008-06-30
US20080045527A1 (en) 2008-02-21
BRPI0408365A (pt) 2006-03-21
NO20054710D0 (no) 2005-10-13
DE602004030225D1 (de) 2011-01-05
WO2004081011A1 (en) 2004-09-23
EA014080B1 (ru) 2010-08-30
HK1090921A1 (en) 2007-01-05
ATE489388T1 (de) 2010-12-15
US20070021428A1 (en) 2007-01-25
KR20050121681A (ko) 2005-12-27
ECSP056104A (es) 2006-03-01

Similar Documents

Publication Publication Date Title
HK1090921A1 (en) Immunomodulating heterocyclic compounds
CY1107168T1 (el) Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar
NL300927I9 (nl) Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
GB2392154B (en) Protein Kinase Inhibitors
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
GB2398781B (en) Kinase inhibitors
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
EA200801381A1 (ru) Производные пиримидина
HK1100659A1 (en) Hiv protease inhibiting compounds hiv
NO20054669L (no) Substituerte kinobenzoxazinanaloger
MXPA05011276A (es) Derivado heterociclico de cinco miembros.
GB0215392D0 (en) Chemical compounds
HK1086835A1 (en) N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
TW200518748A (en) Chemical compounds
WO2004103305A3 (en) Spiropyrazole compound
DOP2002000354A (es) Compuestos farmaceuticamente activos.